FDA Clears Bemotrizinol, the First New Sunscreen Ingredient for Americans in 20 Years

For the first time in about two decades, the U.S. Food and Drug Administration has approved a new sunscreen ingredient, clearing the way for Americans to buy a filter that dermatologists say offers stronger, more durable protection than much of what is currently on store shelves. The ingredient, bemotrizinol — often abbreviated BEMT — has been used in Europe, Asia and other markets for years.

Bemotrizinol is a broad-spectrum filter, meaning it blocks both ultraviolet B rays, which cause sunburn, and the deeper-penetrating ultraviolet A rays. That distinction matters. Traditional American sunscreens are generally effective against UVB but often fall short on UVA, the rays that drive premature skin aging, suppress the immune system and contribute heavily to skin cancer. Bemotrizinol is designed to close that gap, giving U.S. consumers a level of UVA protection that has until now been hard to find on domestic shelves.

The chemical also carries practical advantages, experts say. It is more photostable than many existing chemical filters — meaning it does not break down as quickly in sunlight — and is less likely to be absorbed into the skin and bloodstream, a concern that has dogged some older ingredients. Unlike mineral sunscreens built on zinc oxide or titanium dioxide, it does not leave a chalky white cast, a common complaint that discourages people from applying enough.

The approval is notable in part because of how rare it is. The United States regulates sunscreens as over-the-counter drugs rather than as cosmetics, a stricter framework that has made it enormously difficult and expensive to introduce new active ingredients. As a result, Americans have long had access to a far smaller menu of filters than consumers in Europe, where sunscreens are treated as cosmetics and reformulated more freely.

The FDA framed the move as expanding sunscreen options for the first time in 20 years, part of a broader effort to modernize its approach to sun protection. The agency has signaled it wants to streamline the pathway for additional ingredients that are already widely used abroad, potentially opening the door to more approvals in the coming years.

Manufacturers say the first U.S. products containing bemotrizinol are expected to reach shelves in the fall of 2026. Dermatologists cautioned that no single ingredient is a cure-all and that consistent use, generous application, reapplication and other measures such as protective clothing and shade remain essential. But many welcomed an expanded arsenal against a disease diagnosed in millions of Americans every year, calling it one of the more meaningful shifts in everyday sun protection in a generation.